期刊
JOURNAL OF SURGICAL ONCOLOGY
卷 109, 期 6, 页码 597-605出版社
WILEY
DOI: 10.1002/jso.23544
关键词
sarcoma; imatinib; GIST
资金
- Alfried Krupp von Bohlen und Halbach Foundation
- Hella-Buhler-Foundation
- Dr. Ingrid zu Solms Foundation
- Hector Foundation
- FRONTIER Excellence Initiative of the University of Heidelberg
- Walter Schulz Foundation
- BMBF
- Deutsche Krebshilfe
- DKFZ-MOST German-Israeli Project Cooperation
- Wilhelm-Sander Foundation
Background Increased activity of Src has been found in several human cancers, and often is associated with poor clinical outcome. The present study aimed to determine whether Src activity is increased in gastrointestinal stromal tumors (GIST), and whether it correlates with established tumor or patient characteristics and prognosis. Methods Tumor/normal tissues of 29 patients were analyzed for Src activity/protein with kinase assays, and for VEGF/VEGFR with immunohistochemical staining. Results Src activity was higher in tumor than in normal tissues (P = 0.093). However, when imatinib responders were excluded from the analyses, it was significantly higher in the tumor tissue (P = 0.017). Additionally, it was higher in primary compared to recurrent tumors or metastasis (P = 0.04). Univariate survival analysis showed a longer overall survival for patients with high Src activity (P = 0.038). In multivariate analysis, the response to imatinib treatment was the only survival-influencing factor (P = 0.072). Conclusions Src activity is increased in GIST. In contrast to most other tumor entities, it does not correlate with poor clinical outcome, but decreases during the progression from primary tumor to recurrence and metastasis, especially under therapy with imatinib. Additionally, our results show that higher Src activity is associated with longer overall survival. J. Surg. Oncol. 2014 109:???-???. (c) 2014 Wiley Periodicals, Inc.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据